Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 66

1.

Rotenone, paraquat, and Parkinson's disease.

Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, Marras C, Bhudhikanok GS, Kasten M, Chade AR, Comyns K, Richards MB, Meng C, Priestley B, Fernandez HH, Cambi F, Umbach DM, Blair A, Sandler DP, Langston JW.

Environ Health Perspect. 2011 Jun;119(6):866-72. doi: 10.1289/ehp.1002839. Epub 2011 Jan 26.

2.

Over-expression of alpha-synuclein in the nervous system enhances axonal degeneration after peripheral nerve lesion in a transgenic mouse strain.

Siebert H, Kahle PJ, Kramer ML, Isik T, Schlüter OM, Schulz-Schaeffer WJ, Brück W.

J Neurochem. 2010 Aug;114(4):1007-18. doi: 10.1111/j.1471-4159.2010.06832.x. Epub 2010 May 26.

3.

Suppression of MAP kinases inhibits microglial activation and attenuates neuronal cell death induced by alpha-synuclein protofibrils.

Wilms H, Rosenstiel P, Romero-Ramos M, Arlt A, Schäfer H, Seegert D, Kahle PJ, Odoy S, Claasen JH, Holzknecht C, Brandenburg LO, Deuschl G, Schreiber S, Kirik D, Lucius R.

Int J Immunopathol Pharmacol. 2009 Oct-Dec;22(4):897-909.

PMID:
20074453
4.

Genetic regulation of alpha-synuclein mRNA expression in various human brain tissues.

Linnertz C, Saucier L, Ge D, Cronin KD, Burke JR, Browndyke JN, Hulette CM, Welsh-Bohmer KA, Chiba-Falek O.

PLoS One. 2009 Oct 16;4(10):e7480. doi: 10.1371/journal.pone.0007480.

5.

Neuroinflammation in Parkinson's disease.

Lee JK, Tran T, Tansey MG.

J Neuroimmune Pharmacol. 2009 Dec;4(4):419-29. doi: 10.1007/s11481-009-9176-0. Epub 2009 Oct 10. Review.

6.

Glutamate, excitotoxicity, and programmed cell death in Parkinson disease.

Caudle WM, Zhang J.

Exp Neurol. 2009 Dec;220(2):230-3. doi: 10.1016/j.expneurol.2009.09.027. Epub 2009 Oct 6. Review. No abstract available.

PMID:
19815009
7.

Occupation and risk of parkinsonism: a multicenter case-control study.

Tanner CM, Ross GW, Jewell SA, Hauser RA, Jankovic J, Factor SA, Bressman S, Deligtisch A, Marras C, Lyons KE, Bhudhikanok GS, Roucoux DF, Meng C, Abbott RD, Langston JW.

Arch Neurol. 2009 Sep;66(9):1106-13. doi: 10.1001/archneurol.2009.195.

PMID:
19752299
8.

Enhanced alpha-synuclein expression in human neurodegenerative diseases: pathogenetic and therapeutic implications.

McCormack AL, Di Monte DA.

Curr Protein Pept Sci. 2009 Oct;10(5):476-82. Review.

PMID:
19538156
9.

Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain.

Cronin KD, Ge D, Manninger P, Linnertz C, Rossoshek A, Orrison BM, Bernard DJ, El-Agnaf OM, Schlossmacher MG, Nussbaum RL, Chiba-Falek O.

Hum Mol Genet. 2009 Sep 1;18(17):3274-85. doi: 10.1093/hmg/ddp265. Epub 2009 Jun 4.

10.

Traumatic brain injury and intestinal dysfunction: uncovering the neuro-enteric axis.

Bansal V, Costantini T, Kroll L, Peterson C, Loomis W, Eliceiri B, Baird A, Wolf P, Coimbra R.

J Neurotrauma. 2009 Aug;26(8):1353-9. doi: 10.1089/neu.2008-0858.

11.

Systemic inflammatory response following acute traumatic brain injury.

Lu J, Goh SJ, Tng PY, Deng YY, Ling EA, Moochhala S.

Front Biosci (Landmark Ed). 2009 Jan 1;14:3795-813. Review.

PMID:
19273311
12.

Risk of Parkinson's disease after hospital contact for head injury: population based case-control study.

Rugbjerg K, Ritz B, Korbo L, Martinussen N, Olsen JH.

BMJ. 2008 Dec 15;337:a2494. doi: 10.1136/bmj.a2494.

13.

Distinct cellular patterns of upregulated chemokine expression supporting a prominent inflammatory role in traumatic brain injury.

Israelsson C, Bengtsson H, Kylberg A, Kullander K, Lewén A, Hillered L, Ebendal T.

J Neurotrauma. 2008 Aug;25(8):959-74. doi: 10.1089/neu.2008.0562.

PMID:
18665806
14.

Genomic investigation of alpha-synuclein multiplication and parkinsonism.

Ross OA, Braithwaite AT, Skipper LM, Kachergus J, Hulihan MM, Middleton FA, Nishioka K, Fuchs J, Gasser T, Maraganore DM, Adler CH, Larvor L, Chartier-Harlin MC, Nilsson C, Langston JW, Gwinn K, Hattori N, Farrer MJ.

Ann Neurol. 2008 Jun;63(6):743-50. doi: 10.1002/ana.21380.

15.

Genetic association between alpha-synuclein and idiopathic Parkinson's disease.

Kay DM, Factor SA, Samii A, Higgins DS, Griffith A, Roberts JW, Leis BC, Nutt JG, Montimurro JS, Keefe RG, Atkins AJ, Yearout D, Zabetian CP, Payami H.

Am J Med Genet B Neuropsychiatr Genet. 2008 Oct 5;147B(7):1222-30. doi: 10.1002/ajmg.b.30758.

PMID:
18404644
16.

A nationwide population study of severe head injury and Parkinson's disease.

Spangenberg S, Hannerz H, Tüchsen F, Mikkelsen KL.

Parkinsonism Relat Disord. 2009 Jan;15(1):12-4. doi: 10.1016/j.parkreldis.2008.02.004. Epub 2008 Mar 25.

PMID:
18367422
17.

Exploring gene-environment interactions in Parkinson's disease.

McCulloch CC, Kay DM, Factor SA, Samii A, Nutt JG, Higgins DS, Griffith A, Roberts JW, Leis BC, Montimurro JS, Zabetian CP, Payami H.

Hum Genet. 2008 Apr;123(3):257-65. doi: 10.1007/s00439-008-0466-z. Epub 2008 Jan 22.

PMID:
18210157
18.

Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain.

Fuchs J, Tichopad A, Golub Y, Munz M, Schweitzer KJ, Wolf B, Berg D, Mueller JC, Gasser T.

FASEB J. 2008 May;22(5):1327-34. Epub 2007 Dec 27.

PMID:
18162487
19.

Mitochondria in the aetiology and pathogenesis of Parkinson's disease.

Schapira AH.

Lancet Neurol. 2008 Jan;7(1):97-109. Review.

PMID:
18093566
20.

Neuroinflammatory responses after experimental diffuse traumatic brain injury.

Kelley BJ, Lifshitz J, Povlishock JT.

J Neuropathol Exp Neurol. 2007 Nov;66(11):989-1001.

PMID:
17984681

Supplemental Content

Support Center